• Home
  • Search Results
  • Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer.

Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer.

World journal of gastroenterology (2009-04-11)
Tie-Li Peng, Jie Chen, Wei Mao, Xin Liu, Yu Tao, Lian-Zhou Chen, Min-Hu Chen
ABSTRACT

To determine the functional significance of aryl hydrocarbon receptor (AhR) in gastric carcinogenesis, and to explore the possible role of AhR in gastric cancer (GC) treatment. RT-PCR, real-time PCR, and Western blotting were performed to detect AhR expression in 39 GC tissues and five GC cell lines. AhR protein was detected by immunohistochemistry (IHC) in 190 samples: 30 chronic superficial gastritis (CSG), 30 chronic atrophic gastritis (CAG), 30 intestinal metaplasia (IM), 30 atypical hyperplasia (AH), and 70 GC. The AhR agonist tetrachlorodibenzo-para-dioxin (TCDD) was used to treat AGS cells. MTT assay and flow cytometric analysis were performed to measure the viability, cell cycle and apoptosis of AGS cells. AhR expression was significantly increased in GC tissues and GC cell lines. IHC results indicated that the levels of AhR expression gradually increased, with the lowest levels in CSG, followed by CAG, IM, AH and GC. AhR expression and nuclear translocation were significantly higher in GC than in precancerous tissues. TCDD inhibited proliferation of AGS cells via induction of growth arrest at the G1-S phase. AhR plays an important role in gastric carcinogenesis. AhR may be a potential therapeutic target for GC treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Cytochrome P450 Enzyme CYP1A1 Antibody, serum, Chemicon®

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.